It was found that the domestic approval for oral atopic dermatitis treatment developed by Pfizer is imminent. This product is a JAK inhibitor in the same family as Xeljanz, which is used as a treatment for rheumatoid arthritis. As JAK inhibitors have recently obtained permission with atopy treatment indications one after another, it remains to be seen what Dupixent's sales will be like.

According to the industry on the 21st, the MFDS recently completed safety and effectiveness screening for Pfizer's Cibinqo 50mg (Abrocitinib), an oral atopic treatment. When the review is completed, The approval is expected to be granted soon.

This product was first approved in the UK in August as a modera